Taiwan is one of the leaders in biotech listings: Aslan Pharma CEO

Dr Carl Firth, CEO of ASLAN Pharmaceuticals. Credit: ASLAN Pharmaceuticals.

Singapore-based biotechnology firm Aslan Pharmaceuticals, which focuses on the development of immunotherapies and targeted agents for Asia prevalent tumour types, closed an initial public offering (IPO) in Taiwan via competitive auction.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.